Community-acquired Pneumonia
Conditions
Brief summary
The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.
Detailed description
The efficacy of oral amoxicillin is considered equal to that of ceftriaxone in community-acquired pneumonia among children. Also, there are some factors that contradict the usage of ceftriaxone, like antibiotic resistance, adverse reactions, drug cost, and the and the chances of IV trauma and infection, which is a major problem in developing countries. Therefore, this study was planned to determine the efficacy of oral amoxicillin compared with intravenous (IV) ceftriaxone in the treatment of uncomplicated ceftriaxone in community acquired pneumonia in children less than 5 years of age.
Interventions
DRUGAmoxicillin/CA
Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
DRUGIV ceftriaxone
Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Sponsors
RESnTEC, Institute of Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
No
Inclusion criteria
* Children of both gender * Aged from 2 to 5 years * With fever \>37.5 C (99.5 F) * Will be presented with symptoms and signs of uncomplicated community acquired pneumonia
Exclusion criteria
* Children requiring ICU care (having cyanosis SpO2 \< 85% requiring intubation within first day of admission or in state of shock) * Children with conditions like congenital heart disease, chronic lung disease, chronic kidney disease, severe malnutrition, asthma, foreign bodies, sickle cell disease, and immunodeficiency * Children with underlying anatomical disorders of the lung like pulmonary sequestration, tracheoesophageal fistula or congenital cystic adenoid malformation * Children already on antibiotics * Presence of any complication of community acquired pneumonia * Patients having symptoms of multi-organ involvement/sepsis * Hypersensitivity to Amoxicillin or Ceftriaxone * Other co-existing infections like dengue, malaria, or measles
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Free from fever | 3 days | Efficacy will be labeled yes where fever symptoms are resolved (temperature = 98.6ºF) within 3 days. |
Countries
Pakistan
Contacts
Primary ContactAsim Din, FCPS
Outcome results
None listed